Firmagon (Degarelix) Intermittent Therapy

Summary

Men with localized prostate cancer requiring intermittent androgen deprivation therapy for biochemical recurrence following radical therapy will be asked to participate in a phase 4 safety and efficacy clinical trial comparing 10 months versus 4 months of degarelix (Firmagon®) therapy with the endpoint of prolonging the off treatment interval.

Timeline

Start

2012-01

Primary completion

2018-01

Completion

2018-01

Drugs

Indications